Long Term Follow up of Patients Who Have Received Gene Therapy or Gene Marked Products
study id #: NCT00695279
condition: Severe Combined Immunodeficiency, Malignancy, Hematologic, Neuroblastoma, Neoplasm, Mucopolysaccharidosis I
status: Recruiting
purpose:This protocol (GENEFU) provides a mechanism for the 15-year followup period that the FDA requires for all participants in gene transfer protocols and assures that adequate followup can be maintained for a wide variety of participants on different individual gene therapy protocols at St. Jude Children’s Research Hospital.
GENEFU serves as an umbrella protocol for long-term follow-up (LTFU) for recipients of gene therapy/gene marked (GT/GM) products at St. Jude Children’s Research Hospital. The FDA has recommended methods to assess the risk of delayed adverse events after GT/GM and has provided specific requirements regarding the duration and design of LTFU observations. This protocol is intended to provide LTFU in accordance with the FDA guidelines for those who received a GT/GM product as part of a St. Jude-sponsored clinical trial or compassionate use treatment plan. The protocol calls for a physical examination or general health evaluation and collection of required blood samples annually for up to 15 years after the last receipt of a GT/GM product.
Goals will be to obtain clinical histories in order to detect late clinical outcomes suggestive of retroviral or lentiviral disease, including but not limited to cancer/second malignancies, neurologic disorders, autoimmune disorders, and hematologic disorders. Blood samples will be archived and tested when clinically or scientifically indicated, as in the event of development of a second malignancy. This prospective cohort study will utilize descriptive statistics in the analysis of long-term late effects outcomes. It offers a uniform approach to long-term safety monitoring in research participants who have received a gene-transduced product as part of St. Jude-sponsored GT or GM protocols and compassionate use treatment plans.
intervention: Venipuncture
results: https://clinicaltrials.gov/ct2/show/results/NCT00695279
last updated: February 26, 2022
-
Identification and Structure Characterization of Novel IDS Variants Causing Mucopolysaccharidosis Type II: A Retrosp...Mucopolysaccharidosis type II (MPS II) o...
-
MPS IV MorquioWhat is MPS IV?MPS IV, known as Morquio ...
-
Mucopolysaccharidosis Type I Disease Prevalence Among Patients With Idiopathic Short Stature in Saudi Arabia: Protoc...Since the underlying cause of idiopathic...
-
Mucopolysaccharidosis Type III – Sanfilippo SyndromeMucopolysaccharidosis type III (MPS III)...
-
Mucopolysaccharidosis Conditions Explainedhttps://www.youtube.com/watch?v=EmSJ_hGE...
-
The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-A...Nonrandomized studies are usually exclud...
-
Oxidative Stress in Mucopolysaccharidoses: Pharmacological ImplicationsAlthough mucopolysaccharidoses (MPS) are...